Details of the Drug

General Information of Drug (ID: DMYO3PW)

Drug Name

MRx0518

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25	Phase 1/2	[1]
------------------------------------------------------------------------------------

Drug Type

Live biotherapeutic product

Cross-matching ID

References

1	ClinicalTrials.gov (NCT03637803) Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors. U.S. National Institutes of Health.